Caroline Seymour

Between 2000 and 2018, the number of pancreatic cancer cases rose, particularly among women between the ages of 15 to 35 years.

Ruxolitinib was not associated with an increased risk of secondary malignancies in patients with polycythemia vera.

Patient Reported Outcomes Measurement Information System scoring suggested that wound complication was associated with more severe anxiety and decreased physical function in patients receiving radiation therapy for soft tissue sarcoma.

Although cancer clinical trial enrollment plummeted during the initial wave of the COVID-19 pandemic, study results show that enrollment has rebounded over the past year.

Patients with HER2-positive, metastatic colorectal cancer and higher HER2 expression at baseline experienced improved responses following treatment with trastuzumab deruxtecan.

Interim findings presented at the 2021 ESMO congress suggest that tisotumab vedotin plus frontline carboplatin and second-/third-Line pembrolizumab may be a suitable treatment option for recurrent/metastatic cervical cancer.

Patients with both COVID-19 and malignant pleural mesothelioma showed high rates of hospitalization and mortality.

Zanubrutinib (Brukinsa) is now FDA approved for the treatment of adults with Waldenström Macroglobulinemia.

The continued development of KRAS G12C inhibitors for the treatment of non-small cell lung cancer shows that researchers are making breakthroughs in the treatment landscape.

CDK4/6 inhibitors have demonstrated promise in treating patients with estrogen receptor (ER)–positive, HER2-negative breast cancer in both a neoadjuvant and adjuvant setting.

Patients with multiple myeloma are potentially at greater risk of developing severe COVID-19 after the SARS-COv-2 vaccination induced suboptimal antibody response.

Data from a 5-year follow-up study confirmed that CPX-351 continues to be associated with long-term remission and improved overall survival compared to 7+3 chemotherapy in certain older patients with acute myeloid leukemia.

The combination of drugs resulted in a response from more than half of patients.

The phase 3 SIMPLIFY 1 and SIMPLIFY 2 trials reported that Week 24 transfusion independence resulted in an improved overall survival for patients with myelofibrosis.

The FDA has granted a breakthrough therapy designation to teclistamab for the treatment of patients with relapsed/refractory multiple myeloma.

Age was associated with overall survival and the time to Richter transformation in adolescent and young adult patients with chronic lymphocytic leukemia, according to findings from a single-institutional, retrospective study.

Molecular testing is more essential than ever, thanks to the targeted therapy options for non-small cell lung cancer.

An expert gives an overview of recent advancements in the lung cancer space.

Robert Wenham, MD, MS, FACOG, FACS, discusses the basis for combining chemotherapy, PARP inhibitors, and VEGF inhibitors with immunotherapy in ovarian cancer and ongoing research with ADCs in the field.

Tony Philip, MD, provides insight into the utility of ctDNA in the early-stage setting, trials that could determine its role in clinical practice, and detailed the shift toward nonoperative and less-intensive interventions in the early-stage and advanced settings, respectively.

Olaparib and talazoparib didn't show statistically significant improvements in overall survival compared with chemotherapy in certain patients with metastatic breast cancer. However, the results are unlikely to affect the drugs’ utility in practice, given that both agents continue to show favorable tolerability and disease control.

The KATHERINE, FeDeriCa, DESTINY-Breast01, and HER2CLIMB trials have changed practice for patients with HER2-positive breast cancer for the better.

Since the publication of the pivotal ELIANA trial in pediatric patients with acute lymphoblastic leukemia, the field of CAR T-cell therapy has grown significantly and left providers better equipped to understand and manage treatment-related adverse effects, such as cytokine release syndrome.

Sapanisertib failed to show significant activity and a favorable toxicity profile in patients with refractory metastatic renal cell carcinoma (mRCC) regardless of mTOR or PTEN status.

Combinations of JAK inhibitors and novel agents, such as epigenetic regulators, could help prolong survival in patients with myeloproliferative neoplasms.

The radiographic and pathologic responses that have been seen with checkpoint inhibitors in lung cancer bodes well for the use of neoadjuvant therapy. However, the relationship between response and long-term outcomes, specifically with regard to overall survival, will have to be teased out before they become standard practice, explained David Spigel, MD.

Survival for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) remains poor, and although immunotherapy has been positioned as a holy grail, it would be preemptive to predict its future based on the number of small studies that have been performed to date, according to Amer Zeidan, MD, MHS.

“But our study is pointing to new genes to consider. For example, we found that the BRCA2 gene, typically associated with adult breast and ovarian cancer, may also somehow influence the susceptibility of pediatric RMS.”

The coronavirus disease 2019 (COVID-19) pandemic has become another potential complication for patients with lung cancer, said Mark G. Kris, MD, who added that although the pandemic has disrupted patient care, it has yet to stunt scientific collaboration.